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Abstract 
Obesity is associated with a number of metabolic disorders such as insulin resistance, 
glucose intolerance, and dyslipidaemia. The main objective of this research work 
focused on potential therapeutic applications of “naked” gold nanoparticles (AuNPs) in 
the treatment of obesity-related metabolic diseases. In this thesis, 21 nm spherical 
citrate-coated, unmodified also known as “naked” AuNPs were studied and assessed 
using both in vitro cell and in vivo animal studies. We observed an increased rate of 
“naked” AuNPs cellular uptake non-selectively and non-specific accumulation in all 
cell types studied compared to surface modified AuNPs. Macrophages in adipose tissue 
played a crucial role contributing to the low-grade chronic inflammation present in 
obesity and pathogenesis of obesity-related metabolic disorders. Our in vitro studies 
also showed that AuNPs can act on the complex adipocyte-macrophage interaction 
altering the adipocytes lipid and fatty acid metabolic markers in a macrophage-
dependent manner. 
Based on this unique finding, we further investigated the long-term safety of AuNP 
treatment and their effect on adipose tissue macrophages using in vivo mice model with 
dietary obesity. In this study, 7 week old male C57Bl/6 mice were fed a high fat diet 
(HFD) and received daily intraperitoneal injection of AuNPs (0.785 μg or 7.85 
μg/g/day) for 9 weeks. Our results showed that the AuNP-treated mice with dietary 
obesity showed significantly improved body morphometry measurement with 
significantly reduced blood lipid levels and prevented the development of glucose 
intolerance. We proposed that the alterations in the local pro-inflammatory cytokine 
environment due to modification of macrophage activity by AuNPs may be the key 
underlying mechanism for the weight loss observed in the HFD-fed mice. In addition, 
there was no indication of liver toxicity after 9 weeks of daily AuNPs exposure.  
Following that, male C57Bl/6 mice (7 week old) feeding a 10 week HFD were used as 
an in vivo obese model with chronic obesity and metabolic disorder to study the effect 
of short-term AuNP treatment. At week 10, the obese mice were continued on a HFD 
and AuNP treatment (0.0785 μg, 0.785 μg, or 7.85 μg/g/day) administered daily via 
intraperitoneal injection for an additional 5 weeks. Our findings showed that the 5 
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weeks AuNP-treated obese mice had little to no impact on body morphometric 
measurements of mice with existing obesity. However, all obese mice treated with 5 
weeks of AuNPs showed amelioration of glucose intolerance. Our results also showed 
altered the inflammatory cytokines, lipid, and glucose marker expression in the liver. 
Our findings suggest that obese mice treated with AuNPs could have a lower the risk of 
developing obesity-related complications such as glucose intolerance and liver steatosis. 
This research work demonstrated the anti-obesity and anti-diabetic properties of AuNPs 
which has led to our proposal that AuNPs can serve as a novel therapeutic treatment 
strategy in the prevention of obesity and obesity-related metabolic disorders.  
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DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
dNTP deoxyucleotide 
DPBS dulbecco's PBS 
EDTA ethylenediaminetetraacetic acid 
EDC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
F4/80 expressing ATMs 
FASN fatty acid synthase 
FBS fetal bovine serum 
FOX forkhead box 
GLUT glucose transporter 
GM-CSF granulocyte-macrophage colony-stimulating factor 
H&E harris haematoxylin and eosin 
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H2-DCFDA 2’,7’-dicholorofluorescein diacetate 
HAuCl4 tetrachlorouauric acid 
HCAEC human coronary artery endothelial cell 
HFD high fat diet 
HFD-C HFD-fed mice control 
HFD-HAu HFD-fed mice treated with high doses AuNPs 
HFD-LAu HFD-fed mice treated with low dose of AuNPs 
HRP horseradish peroxidase 
HR-SEM high resolution scanning electron microscopy 
ICP-MS inductively–coupled plasma mass spectroscopy 
IFN interferon 
IKK inhibitory kappa kinase 
IL interleukin 
IP intraperitoneal 
IPGTT intraperitonoteal glucose tolerance test 
IκB inhibitory kappaB 
LPS lipopolysaccharide 
M1 pro-inflammatory macrophage 
M2 anti-inflammtory macrophage 
MES 2-(N-morpholino)ethanesulfonic acid 
MΦ macrophage 
MPC monolayer protected cluster 
mRNA messenger RNA 
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MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NCS new calf serum 
NEFA non-esterified fatty acid 
NF-κB nuclear factor-kappa B 
NHS N-hydroxysuccinimide 
OB-C obese mice control 
OB-EAu obese mice treated with extremely low dose of AuNPs 
OB-HAu obese mice treated with high dose of AuNPs 
OB-LAu obese mice treated with low dose of AuNPs 
P/S penicillin and streptomycin 
PBS phosphate buffered saline 
PC pre-adipocyte or 3T3-L1 fibroblast control 
PCR polymerase chain reaction 
PEG polyethelyne glycol 
PEPCK phosphoenolpyruvate carboxykinase 
pf-DMEM phenol-red free Dulbecco’s Modified Eagle Medium 
PMA phorbol 12-myristate 13-acetate 
PPAR peroxisome proliferator-activated receptor 
RMΦ RAW 264.7 macrophages 
RMΦC RAW 264.7 macrophages control 
RMΦH RAW 264.7 macrophages treated with high dose of AuNPs 
RMΦHH 
RAW 264.7 macrophages treated with extremely high dose of 
AuNPs 
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RMΦL RAW 264.7 macrophages treated with low dose of AuNPs 
RMΦLPSH high dose LPS stimulated RAW 264.7 macrophage 
RMΦLPSL low dose LPS stimulated RAW 264.7 macrophages 
RNA ribonucleic acid 
ROS reaction oxygen speacies 
RPMI roswell park memorial institute 
RT-PCR real-time PCR 
S.E.M standard mean of error 
SAA serum amyloid A 
SPR surface plasmon resonance 
SREBP sterol regulatory element binding protein 
TEM transmission electron microscopy 
TLR-4 toll-like receptor-4 
TNF tumor necrosis factor 
UMΦ U937 monocytes 
UMΦC PMA-differentiated U937 control 
UMΦC_LPS PMA-differentiated U937 with LPS stimulation control 
UMΦH PMA-differentiated U937 treated with high dose AuNP 
UMΦH_LPS PMA-differentiated U937 treated with high dose AuNPs and LPS 
UMΦ_HH PMA-differentiated U937 treated-with extremely high dose AuNPs 
UMΦ_HH_LPS 
PMA-differentiated U937 treated with extremely high dose AuNPs 
and LPS 
UMΦL PMA-differentiated U937 treated with low dose AuNPs 
  
